Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
PCSK9: A Key Modulator of Cardiovascular HealthCirculation research, 2014-03, Vol.114 (6), p.1022-1036 [Peer Reviewed Journal]2014 American Heart Association, Inc. ;ISSN: 0009-7330 ;EISSN: 1524-4571 ;DOI: 10.1161/CIRCRESAHA.114.301621 ;PMID: 24625727Full text available |
|
2 |
Material Type: Article
|
Targeting the Proprotein Convertase Subtilisin/Kexin Type 9 for the Treatment of Dyslipidemia and AtherosclerosisJournal of the American College of Cardiology, 2013-10, Vol.62 (16), p.1401-1408 [Peer Reviewed Journal]American College of Cardiology Foundation ;2013 American College of Cardiology Foundation ;2015 INIST-CNRS ;Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Oct 15, 2013 ;ISSN: 0735-1097 ;EISSN: 1558-3597 ;DOI: 10.1016/j.jacc.2013.07.056 ;PMID: 23973703 ;CODEN: JACCDIFull text available |
|
3 |
Material Type: Article
|
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition: A New Therapeutic Mechanism for Reducing Cardiovascular Disease RiskCirculation (New York, N.Y.), 2015-10, Vol.132 (17), p.1648-1666 [Peer Reviewed Journal]2015 by the American College of Cardiology Foundation and the American Heart Association, Inc. ;2015 American Heart Association, Inc. ;ISSN: 0009-7322 ;EISSN: 1524-4539 ;DOI: 10.1161/CIRCULATIONAHA.115.016080 ;PMID: 26503748Full text available |
|
4 |
Material Type: Article
|
Revisiting Proinsulin Processing: Evidence That Human β-Cells Process Proinsulin With Prohormone Convertase (PC) 1/3 but Not PC2Diabetes (New York, N.Y.), 2020-07, Vol.69 (7), p.1451-1462 [Peer Reviewed Journal]2020 by the American Diabetes Association. ;Copyright American Diabetes Association Jul 1, 2020 ;ISSN: 0012-1797 ;EISSN: 1939-327X ;DOI: 10.2337/db19-0276 ;PMID: 32291281Full text available |
|
5 |
Material Type: Article
|
The PCSK9 decadeJournal of lipid research, 2012-12, Vol.53 (12), p.2515-2524 [Peer Reviewed Journal]2012 © 2012 ASBMB. Currently published by Elsevier Inc; originally published by American Society for Biochemistry and Molecular Biology. ;ISSN: 0022-2275 ;EISSN: 1539-7262 ;DOI: 10.1194/jlr.R026658 ;PMID: 22811413Full text available |
|
6 |
Material Type: Article
|
Effect of a Monoclonal Antibody to PCSK9 on LDL CholesterolThe New England journal of medicine, 2012-03, Vol.366 (12), p.1108-1118 [Peer Reviewed Journal]Copyright © 2012 Massachusetts Medical Society. All rights reserved. ;2015 INIST-CNRS ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1105803 ;PMID: 22435370 ;CODEN: NEJMAGFull text available |
|
7 |
Material Type: Article
|
A Highly Durable RNAi Therapeutic Inhibitor of PCSK9The New England journal of medicine, 2017-01, Vol.376 (1), p.41-51 [Peer Reviewed Journal]Copyright © 2016 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1609243 ;PMID: 27959715Full text available |
|
8 |
Material Type: Article
|
Mouse Models of Human Proprotein Convertase InsufficiencyEndocrine reviews, 2021-06, Vol.42 (3), p.259-294 [Peer Reviewed Journal]The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2020 ;The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. ;COPYRIGHT 2021 Oxford University Press ;The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com ;ISSN: 0163-769X ;EISSN: 1945-7189 ;DOI: 10.1210/endrev/bnaa033 ;PMID: 33382413Full text available |
|
9 |
Material Type: Article
|
Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell LineThe Journal of biological chemistry, 2016-02, Vol.291 (7), p.3508-3519 [Peer Reviewed Journal]2016 © 2016 ASBMB. Currently published by Elsevier Inc; originally published by American Society for Biochemistry and Molecular Biology. ;2016 by The American Society for Biochemistry and Molecular Biology, Inc. ;2016 by The American Society for Biochemistry and Molecular Biology, Inc. 2016 The American Society for Biochemistry and Molecular Biology, Inc. ;ISSN: 0021-9258 ;EISSN: 1083-351X ;DOI: 10.1074/jbc.M115.664706 ;PMID: 26668321Full text available |
|
10 |
Material Type: Article
|
Lipid-Reduction Variability and Antidrug-Antibody Formation with BococizumabThe New England journal of medicine, 2017-04, Vol.376 (16), p.1517-1526 [Peer Reviewed Journal]Copyright © 2017 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1614062 ;PMID: 28304227Full text available |
|
11 |
Material Type: Article
|
Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trialThe Lancet (British edition), 2014-01, Vol.383 (9911), p.60-68 [Peer Reviewed Journal]Elsevier Ltd ;2014 Elsevier Ltd ;2015 INIST-CNRS ;Copyright © 2014 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jan 4, 2014 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(13)61914-5 ;PMID: 24094767 ;CODEN: LANCAOFull text available |
|
12 |
Material Type: Article
|
PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the futureEuropean heart journal, 2015-09, Vol.36 (36), p.2415-2424 [Peer Reviewed Journal]Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2015. For permissions please email: journals.permissions@oup.com. ;ISSN: 0195-668X ;EISSN: 1522-9645 ;DOI: 10.1093/eurheartj/ehv174 ;PMID: 25971287Full text available |
|
13 |
Material Type: Article
|
A 52-Week Placebo-Controlled Trial of Evolocumab in HyperlipidemiaThe New England journal of medicine, 2014-05, Vol.370 (19), p.1809-1819 [Peer Reviewed Journal]Copyright © 2014 Massachusetts Medical Society. All rights reserved. ;2015 INIST-CNRS ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1316222 ;PMID: 24678979 ;CODEN: NEJMAGFull text available |
|
14 |
Material Type: Article
|
PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunctionJournal of lipid research, 2018-02, Vol.59 (2), p.207-223 [Peer Reviewed Journal]2018 Copyright © 2018 by the American Society for Biochemistry and Molecular Biology, Inc. ;Copyright © 2018 by the American Society for Biochemistry and Molecular Biology, Inc. ;Copyright Journal of Lipid Research Feb 2018 ;Copyright © 2018 by the American Society for Biochemistry and Molecular Biology, Inc. 2018 ;ISSN: 0022-2275 ;EISSN: 1539-7262 ;DOI: 10.1194/jlr.M078360 ;PMID: 29180444Full text available |
|
15 |
Material Type: Article
|
Inhibition of PCSK9 Transcription by Berberine Involves Down-regulation of Hepatic HNF1α Protein Expression through the Ubiquitin-Proteasome Degradation PathwayThe Journal of biological chemistry, 2015-02, Vol.290 (7), p.4047-4058 [Peer Reviewed Journal]2015 © 2015 ASBMB. Currently published by Elsevier Inc; originally published by American Society for Biochemistry and Molecular Biology. ;2015 by The American Society for Biochemistry and Molecular Biology, Inc. ;2015 by The American Society for Biochemistry and Molecular Biology, Inc. 2015 ;ISSN: 0021-9258 ;EISSN: 1083-351X ;DOI: 10.1074/jbc.M114.597229 ;PMID: 25540198Full text available |
|
16 |
Material Type: Article
|
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL CholesterolThe New England journal of medicine, 2017-04, Vol.376 (15), p.1430-1440 [Peer Reviewed Journal]Copyright © 2017 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1615758 ;PMID: 28306389Full text available |
|
17 |
Material Type: Article
|
Low-Density Lipoprotein Cholesterol―Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia: The Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) Randomized TrialCirculation (New York, N.Y.), 2012-11, Vol.126 (20), p.2408-2417 [Peer Reviewed Journal]2015 INIST-CNRS ;ISSN: 0009-7322 ;EISSN: 1524-4539 ;DOI: 10.1161/CIRCULATIONAHA.112.144055 ;PMID: 23129602 ;CODEN: CIRCAZFull text available |
|
18 |
Material Type: Article
|
Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert PanelJournal of the American College of Cardiology, 2018-08, Vol.72 (6), p.662-680 [Peer Reviewed Journal]Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Aug 7, 2018 ;ISSN: 0735-1097 ;EISSN: 1558-3597 ;DOI: 10.1016/j.jacc.2018.05.044 ;PMID: 30071997Full text available |
|
19 |
Material Type: Article
|
PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse LiverArteriosclerosis, thrombosis, and vascular biology, 2015-12, Vol.35 (12), p.2517-2525 [Peer Reviewed Journal]2015 American Heart Association, Inc. ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 1079-5642 ;EISSN: 1524-4636 ;DOI: 10.1161/ATVBAHA.115.306032 ;PMID: 26494228Full text available |
|
20 |
Material Type: Article
|
In vivo genome editing using Staphylococcus aureus Cas9Nature (London), 2015-04, Vol.520 (7546), p.186-191 [Peer Reviewed Journal]COPYRIGHT 2015 Nature Publishing Group ;COPYRIGHT 2015 Nature Publishing Group ;Copyright Nature Publishing Group Apr 9, 2015 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/nature14299 ;PMID: 25830891 ;CODEN: NATUASFull text available |